
Stemtech Corporation
Share · US85859W1027 (OTC)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Stemtech Corporation
No Price
Closing Price OTC 28.04.2026:
0,0002 USD
28.04.2026 18:19
Current Prices from Stemtech Corporation
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
UTC |
STEK
|
USD
|
28.04.2026 18:19
|
0,0002 USD
| 0,00 USD |
Company Profile for Stemtech Corporation Share
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. The company is based in Miramar, Florida.
Company Data
Name Stemtech Corporation
Company Stemtech Corporation
Website
https://www.stemtech.com
Primary Exchange
UTC
ISIN US85859W1027
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Charles S. Arnold
Country United States of America
Currency USD
Employees 0,0 T
Address 10370 USA Today Way, 33025 Naples
IPO Date 2021-11-26
Stock Splits
| Date | Split |
|---|---|
| 05.08.2021 | 1:20 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | STEK |
More Shares
Investors who hold Stemtech Corporation also have the following shares in their portfolio:

